Table 1.
Association Study Cohort Sizes in Essential Tremor (ET) Genetics Research
| Study | ET n | Control n | ET Cohort Source | Overall Result |
| ETM1 | ||||
| HS1-BP3 828C→G variant | 49 | 92 | United States | Negative |
| Shatunov et al, 200563 | ||||
| HS1-BP3 828C→G variant | 73 | 304 | United States | Positive |
| Higgins et al, 200661 | Note initial 2005 report from same group with G variant in ET cases in 2 of 21 US ET families, not ET or unaffecteds in the other families, and not 150 US controls or 73 ET Singaporean cases | |||
| HS1-BP3 828C→G variant | 222 | 132 | United States | Negative |
| Deng et al, 200562 | ||||
| ETM2 | ||||
| ETM2 sequence variants | 30 | 30 | Korean | Positive |
| Kim et al, 200537 | ||||
| ETM2 polymorphisms | 61 | 68 | Czech | Negative |
| Zahorakova et al, 201038 | ||||
| DRD3 312A→G variant | 104 | 116 | Latvian | Negative |
| Inashkina et al, 200839 | ||||
| DRD3 312A→G variant | 116 | 158 | Italian | Negative |
| Vitale et al, 200870 | ||||
| DRD3 312A→G variant | 163 | 192 | Singaporean | Negative |
| Tan et al, 200768 | ||||
| DRD3 312A→G variant | 201 | 282 | Spanish | Positive |
| Garcia-Martin et al, 200966 | ||||
| DRD3 312A→G variant | 276 | 184 | United States | Positive |
| Jeanneteau et al, 200665 | 30 | 50 | French | |
| DRD3 312A→G variant | 299 | 528 | German, Danish, French | Negative |
| Lorenz et al, 200969 | ||||
| DRD3 312A→G variant | 433 | 272 | United States | Negative |
| Blair et al, 200867 | ||||
| LINGO genes | ||||
| LINGO1 rs9652490 and rs11856808 | 109 | 430 | Chinese Han | Negative |
| Zuo et al, 201054 | ||||
| LINGO1 rs9652490 | 117 | 160 | Chinese | Negative |
| Wu et al, 201157 | Note combining with Tan et al53 plus unpublished data into 307 ET and 804 control, meta-analysis positive | |||
| LINGO1 rs9652490 | 141 | 130 | Latvian | Positive |
| Radovica et al, 201252 | 9 other SNPs including rs11856808 negative | |||
| LINGO4 variants | 150 | 300 | Chinese Han | Negative |
| Liang et al, 201259 | ||||
| LINGO1 rs9652490 | 190 | 733 | Singaporean | Positive |
| Tan et al, 200953 | ||||
| LINGO1 rs9652490 and rs11856808 | 226 | 1117 | Spanish | Negative |
| Lorenzo-Betancor et al, 201155 | ||||
| LINGO1 SNPs | 257 | 265 | United States | Positive for rs9652490 and others |
| Clark et al, 201051 | Negative for rs11856808 and others out of 15 SNPs total | |||
| Note meta-analysis combining 3 or 4 published cohorts46, 50, 51, 53 also positive | ||||
| LINGO1 rs9652490 and rs11856808 | 259 | 479 | French Canadian | Negative |
| Bourassa et al, 201156 | ||||
| LINGO2 variants | 327 | 499 | Chinese, Singaporean | Positive for rs7033345 and rs10812774 of 8 variants |
| Wu et al, 201158 | ||||
| LINGO1 SNPs | 332 | 574 | German, French | Positive for rs9652490 and 1 other |
| Thier et al, 201048 | Negative for rs11856808 and others out of 10 SNPs total | |||
| LINGO1 rs9652490 | 356 | 428 | North American | Positive |
| Vilarino-Guell et al, 201050 | ||||
| GWAS | 452 | 14,394 | Icelandic | Positive for LINGO1 rs9652490 and rs11856808 in initial cohort; rs9652490 only in confirmatory cohorts |
| Stefansson et al, 200946 | 281 | 1188 | Austrian, German, United States | |
| LINGO1 and LINGO2 variants | 1247 | 642 | North American | Positive for LINGO1 rs9652490 and 4 others of 16 total, and LINGO2 rs1412229 alone of 21. |
| Vilarino-Guell et al, 201049 | ||||
| SNCA | ||||
| REP1 length | 46 | 100 | United States | Positive |
| Tan et al, 200075 | ||||
| SNCA variants | 106 | 90 | Italian | Negative |
| Pigullo et al, 200390 | ||||
| SNCA variants | 647 | 1285 | North American | Negative |
| Ross et al, 201191 | ||||
| Other variants | ||||
| GABAAR subunit genes variants | 200 | 250 | Spanish | Negative |
| Garcia-Martin et al, 201194, 95 | ||||
| GABAAR subunits and GABA transporter genes variants | 503 | 818 | German, Dutch | Negative |
| Thier et al, 201193 | ||||
| HNMT rs11558538 | 204 | 295 | Spanish | Positive |
| Ledesma et al, 200896 | ||||
| HNMT rs11558538 | 338 | 409 | North American | Negative |
| Keeling et al, 201097 |
Studies are grouped under genetic categories, and listed by first author and year of publication. Within hypothesis groups, studies are ordered by ET n. If the study combined cohorts in one analysis then the full ET n is used. If the same study used different cohorts in different analyses, the larger ET n is listed first. ET cohort source is geographical; some papers have further details on ethnicity. North American = United States and Canada. Overall result considers the main thrust of the study, with a few further notations; see text for comments on age of onset influences, and cited references for full study results details including specific genetic variants tested, haplotype analyses, methods.
Abbreviations: DRD3, dopamine D3 receptor gene; ET, essential tremor; ETM, Hereditary Essential Tremor, Online Mendelian Inheritance of Man (OMIM) locus designation; GABA, gamma-aminobutyric acid; GABAAR, gamma-aminobutyric acid A receptor; HNMT, histamine N-methyltransferase gene; HS1-BP3, HS1 binding protein 3 gene; LINGO, leucine-rich repeat- and Ig domain-containing Nogo receptor-interacting protein; numbered italicized LINGOs are genes encoding LINGO proteins; REP1, mixed dinucleotide repeat sequence in the SNCA promoter region; SNCA, gene encoding α-synuclein; SNPs, single nucleotide polymorphisms; US, United States.
Table 2.
Consequences of Basic Essential Tremor (ET) Features Create Challenges for ET Genetics Research. The current ET clinical definition has a direct impact on ET research. Ways to move forward acknowledge and address these challenges.
| Current ET Feature | Consequences | Possible Responses | Challenges | Moving Forward |
| Phenocopies:High prevalenceMultiple genetic lociUnknown genotypes | Creates false positivesLowers LOD scoreIncreased type 1 errorOne genetic variant may have large phenotypic range (genocopies). | Test different phenotype features or subsets against genotype data (see also Table 3).Use inclusive varied phenotype as outcome rather than narrow ET definition. | How to make phenotype groups more genetically homogeneous is currently unknown.Expanding or narrowing possible phenotypes may or may not increase genetic homogeneity within groups. | Research definitions, specify ET subsets, accept potential even “non-ET” phenotype variables as part of hypotheses generation and testing, use phenotype variables across clinical diagnoses.Experimental design goals are to broaden testable hypotheses, thus move past the potential stalemate of as yet unknown phenotype-genotype connections. |
| Increasing prevalence with age | Creates false negativesLowers LOD scoreIncreased type 2 error | Consider all familial unaffected subjects as unknown.Restrict controls to older ages. | Strict affected status assignments can greatly impact power.Lowers impact of this error type but does not eliminate it. | Prospective studies of age of onset may change perspective on this ET feature.Large collaborative efforts particularly on control data and family member data help improve power and get past this ET feature. |
| ET is a clinical diagnosis:Tremor self-reportingLack of any tremor data particularly for controlsET misdiagnoses:Other disorders;mild tremor versus normal | False negativesFalse negativesFalse positives and false negatives | Prospective longitudinal primary exam dataDirect exams of all subjects: case, control, family memberLarger sample sizes to improve ability to detect associationsUtilizing possible / probable / definite categories, restricting analysis to definite cases | Detailed longitudinal phenotyping requires high investment in time and funds.Both subject and researcher resources impact feasibility of extended direct exams.Large sample sizes are expensive and time consuming to collect.There is always uncertainty in a clinical diagnosis, especially with mild tremor, and comparing to other clinically defined movement disorders.Some level of mechanistic heterogeneity likely in all case and control groups. | Collaborative efforts between: multiple centers; movement disorders experts and genetics experts; researchers and ET research participants.Collaborative efforts to define minimal and additional phenotype data, minimal and additional biosample amounts and time points.Explicit review of feasibility versus data quality tradeoffs to understand choices for each experiment: Non-blinded exams may cause ascertainment bias; time burden for subjects may limit phenotype data; scoring videos rather than in person exams may lower some phenotype data quality but improve blinding and allow multiple examiners; definite-only ET case definition may strengthen result but impact power.Use experimental design process to broaden range of testable hypotheses as above. |
Table 3.
Moving Past Underlying Assumptions in Essential Tremor (ET) Genetics Research. Many research groups are responding to early assumptions about ET with new approaches and theories. This process uncovers further challenges to advancing ET genetics research.
| Assumption | Possible Responses | Challenges | Moving Forward |
| ET is a simple, known phenotypeBasic binary ET / no ET phenotype groups are adequate for genetic analyses | Collect range of motor and non-motor phenotype data“Sporadic” versus “familial”Early age of onsetClassic ET versuscomplicated ETET-PDET-parkinsonismET-dystonia | ET is tremor in isolation by clinical definitionMay not be currently useful, often ill defined.Retrospective data, large differences in actual tremor age of onset versus bothersome increased tremor symptoms reported as age of onset.ET is tremor in isolation by clinical definitionET and PD may or may not be related disorders; ET and PD are common mutual misdiagnoses.ET is tremor in isolation by clinical definition; ET and PD may or may not be related disordersIsolated head tremor is ET by clinical definition, but could be cervical dystonia; ET and limb dystonia misdiagnoses versus ET plus dystonia in non-tremor area. | Use of research phenotype features rather than clinical diagnosis criteriaIf “familial” subset used, clear definition with how family history data obtained.Longitudinal prospective data would strengthen this considerably.Use of research phenotype features rather than clinical diagnosis criteria.Record ET, PD, and dystonia exam features; then able to exclude ET-PD or dystonia cases from genetics studies, or focus on an ET-PD, ET-parkinsonism, or ET-dystonia subset depending on hypothesis.Longitudinal prospective studies with neuropathology will best address research questions. |
| ET is a family of autosomal dominant disorders caused by a small number of common genetic variants | Many rare genetic variants, alone and in combination, are behind much of ET.Epigenetic or other novel hypotheses for disease transmission | Detecting different types of genetic risk factors and causal mutationsAddressing non-mendelian inheritance at a complex biological data level | Collaborative phenotype-genotype studies with multiple research groups to achieve large sample numbers and rich prospective longitudinal phenotype data.High-throughput next generation genetic sequencing (exome, genome), epigenetic (methylome) and data analysis techniques. |
| ET research subjects do not want to or need to understand genetic research at its current level, as no causal mutations are known. | ET community research concerns may strengthen phenotyping and genetics experiment approaches.Return genetic research results information to research subjects and ET community. | ET community concerns may not be relevant to phenotype-genotype experiment design.How to return complex genetic data information to research subjects is not straightforward. | Understand ET community research goals, ET subject observations about ET phenotype and inheritance.Improve education of ET community on goals and results of genetics research, to increase motivated informed participation in genetics research studies. |
